Modality
mAb
MOA
DLL3 ADC
Target
BTK
Pathway
STING
T2DLNMDS
Development Pipeline
Preclinical
~Jul 2017
→ ~Oct 2018
Phase 1
~Jan 2019
→ ~Apr 2020
Phase 2
Jul 2020
→ Jan 2029
Phase 2Current
NCT05606392
2,575 pts·MDS
2020-07→2029-01·Completed
2,575 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-01-192.8y awayPh2 Data· MDS
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029
P2
Complet…
Catalysts
Ph2 Data
2029-01-19 · 2.8y away
MDS
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05606392 | Phase 2 | MDS | Completed | 2575 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| RHH-8482 | Roche | Phase 1 | BTK | |
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| Rimamavacamten | Merck & Co | Phase 1 | PI3Kα | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| 369-8021 | Hansoh Pharma | Approved | BTK | |
| Pemitinib | Xenon Pharma | Preclinical | BTK | |
| Tixatapinarof | Arvinas | Phase 1/2 | CDK2 | |
| Terazumab | Rapport Ther | Phase 2 | BTK |